Teriflunomide: an oral therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis

Costa, Gloria Dalla; Comi, Giancarlo

doi:10.1080/14737175.2023.2229953

Cited by 2 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It did, however, show a reduction in new or enlarged MRI lesions by 55% compared to placebo. While teriflunomide has a generally acceptable safety profile, some possible adverse effects associated with its use include pancreatitis and hepatotoxicity [52,80]. In 2021, EMA approved teriflunomide for treatment of POMS patients aged 10-17 years old, while the FDA rejected its application in pediatric patients due to insufficient data [81,82].…”

Section: Teriflunomidementioning

confidence: 99%

Current and Emerging Treatment Options in Pediatric Onset Multiple Sclerosis

Mavridi,

Bompou,

Redmond

et al. 2024

Sclerosis

View full text Add to dashboard Cite

Pediatric onset multiple sclerosis (POMS), characterized by the onset of multiple sclerosis before the age of 18, is gaining increased recognition. Approximately 5 percent of MS cases manifest before the age of 18, with less than 1 percent occurring before the age of 10. Despite its rarity, pediatric MS exhibits distinct characteristics, with an association between younger age at onset and a comparatively slower disease progression. Despite this slower progression, individuals with POMS historically reach disability milestones at earlier ages than those with adult-onset multiple sclerosis. While various immunomodulatory agents demonstrate significant benefits in MS treatment, such as reduced relapse rates and slower accumulation of brain lesions on magnetic resonance imaging (MRI), the majority of disease-modifying therapies (DMTs) commonly used in adult MS lack evaluation through pediatric clinical trials. Current evidence is predominantly derived from observational studies. This comprehensive review aims to consolidate existing knowledge on the mechanisms of action, efficacy, safety profiles, and recommended dosages of available DMTs specifically in the context of pediatric MS. Furthermore, this review outlines recent advancements and explores potential medications still in developmental stages, providing a thorough overview of the current landscape and future prospects for treating POMS.

show abstract

Section: Teriflunomidementioning

confidence: 99%